Yucai Wang, MD, PhD

Assistant Professor of Medicine, Assistant Professor of Oncology
Mayo Clinic

Dr. Yucai Wang is an Assistant Professor of Medicine and Oncology at Mayo Clinic, Rochester, MN. He is a Consultant in the Division of Hematology and specializes in lymphoma, CLL, and CAR T-cell therapy. Dr. Wang is the Co-Chair of the Lymphoma Committee of Academic and Community Cancer Research United (ACCRU) and is a member of the ECOG Lymphoma Core Committee. Dr. Wang’s research interest includes clinical trials of novel therapies and translational genetic and immunological studies in B-cell malignancies. He is currently the PI of 3 investigator-initiated trials and serves as site PI of more than 10 multicenter trials. His research is funded by Conquer Cancer, NCI, Industry, and Mayo Clinic.

Poster(s):

• 1121 - Safety of concomitant delivery of radiotherapy for second primary malignancy in patients with chronic lymphocytic leukemia treated with continuous novel agents

• 1122 - Treatment Patterns and Outcomes of Patients with TP53-Mutated Chronic Lymphocytic Leukemia

• 1160 - Clinical outcomes in patients with chronic lymphocytic leukemia (CLL) treated with venetoclax-based regimens

• 1229 - A Study of Frontline Therapy in Adults Aged 80+ Years with Chronic Lymphocytic Leukemia (CLL)

• 2011 - Long-term Safety with ≥12 Months of Pirtobrutinib in Relapsed/Refractory (R/R) B-Cell Malignancies

• 3004 - A Phase 2 Study of Minimal Residual Disease-Guided, Time-Limited, First-Line Therapy of Chronic Lymphocytic Leukemia with Pirtobrutinib and Venetoclax (MIRACLE)

• 3005 - BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (trial in progress)